Literature DB >> 12151133

Community-directed treatment with ivermectin in two Nigerian communities: an analysis of first year start-up processes, costs and consequences.

Obinna Onwujekwe1, Reginald Chima, Elvis Shu, Paul Okonkwo.   

Abstract

OBJECTIVES: To determine the start-up processes, costs and consequences of community-directed treatment with ivermectin (CDTI) in two onchocerciasis endemic rural towns of Southeast Nigeria; namely Achi and Nike. The other objectives were to discover the community-financing mechanisms, local ivermectin distribution strategies and communities' organisational capacity to handle the programme.
METHODS: Structured questionnaires, informal interviews, observations, discussions with community members at general village assemblies and community outreach lectures were used at different stages of the study. RESULT: The towns had the organisational capacity to implement the programme. Coverage with ivermectin was between 31-73% in Achi (mean = 58.6%), and 36.6-72% in Nike (mean = 61.95%). The unit financial costs were $0.17 in Nike and $0.13 in Achi, but the unit aggregate cost was $0.37 in Nike and $0.39 in Achi. When research costs were removed, the unit aggregate cost was $0.22 in Achi and $0.20 in Nike. Provider's financial costs and communities' non-financial costs were the biggest contributors to the aggregate cost. The cost would decrease in subsequent years since the research cost and parts of the mobilisation and training costs would not be incurred after the first year.
CONCLUSION: Governments and sponsors of CDTI should find means of continuously strengthening the programme and providing technical support to the communities. As both CDTI and communities are dynamic entities, continuous health education campaigns are needed to keep reminding the people of the benefit of long-term ivermectin distribution, together with the need for community ownership of the programme.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12151133     DOI: 10.1016/s0168-8510(01)00226-3

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  6 in total

Review 1.  The state of health economic evaluation research in Nigeria: a systematic review.

Authors:  Paul Gavaza; Karen L Rascati; Abiola O Oladapo; Star Khoza
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Increasing coverage of insecticide-treated nets in rural Nigeria: implications of consumer knowledge, preferences and expenditures for malaria prevention.

Authors:  Obinna Onwujekwe; Benjamin Uzochukwu; Nkoli Ezumah; Elvis Shu
Journal:  Malar J       Date:  2005-07-18       Impact factor: 2.979

3.  African Programme For Onchocerciasis Control 1995-2015: model-estimated health impact and cost.

Authors:  Luc E Coffeng; Wilma A Stolk; Honorat G M Zouré; J Lennert Veerman; Koffi B Agblewonu; Michele E Murdoch; Mounkaila Noma; Grace Fobi; Jan Hendrik Richardus; Donald A P Bundy; Dik Habbema; Sake J de Vlas; Uche V Amazigo
Journal:  PLoS Negl Trop Dis       Date:  2013-01-31

4.  National mass drug administration costs for lymphatic filariasis elimination.

Authors:  Ann S Goldman; Victoria H Guisinger; Moses Aikins; Maria Lourdes E Amarillo; Vicente Y Belizario; Bertha Garshong; John Gyapong; Conrad Kabali; Hussein A Kamal; Sanjat Kanjilal; Dominique Kyelem; Jefrey Lizardo; Mwele Malecela; Godfrey Mubyazi; P Abdoulaye Nitièma; Reda M R Ramzy; Thomas G Streit; Aaron Wallace; Molly A Brady; Richard Rheingans; Eric A Ottesen; Anne C Haddix
Journal:  PLoS Negl Trop Dis       Date:  2007-10-31

5.  The cost of annual versus biannual community-directed treatment of onchocerciasis with ivermectin: Ghana as a case study.

Authors:  Hugo C Turner; Mike Y Osei-Atweneboana; Martin Walker; Edward J Tettevi; Thomas S Churcher; Odame Asiedu; Nana-Kwadwo Biritwum; María-Gloria Basáñez
Journal:  PLoS Negl Trop Dis       Date:  2013-09-19

6.  Valuing the Unpaid Contribution of Community Health Volunteers to Mass Drug Administration Programs.

Authors:  Hugo C Turner; Jaspreet Toor; Alison A Bettis; Adrian D Hopkins; Shwe Sin Kyaw; Obinna Onwujekwe; Guy E Thwaites; Yoel Lubell; Christopher Fitzpatrick
Journal:  Clin Infect Dis       Date:  2019-04-24       Impact factor: 9.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.